Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2018 | Asciminib: overcoming TKI resistance and reducing toxicity in CML

Asciminib, a new TKI, is being investigated in combination with imatinib in chronic phase chronic myeloid leukemia (CML) currently (NCT03578367). Timothy Hughes, MD, FRACP, FRCPA, of the Royal Adelaide Hospital, Adelaide, Australia, gives us an update on this exciting development here. Speaking from the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting in Houston, TX, Prof. Hughes discusses the drug’s mechanism of action; as an allosteric inhibitor of BCR-ABL, it is less susceptible to the typical mutations driving TKI resistance and is more specific so has a lower toxicity. He also explores where in the treatment sequence asciminib would be best placed.